Reducing Cardiometabolic Risk: What Cardiovascular Outcomes Trials Tell Us About Incretin-Based Therapies

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care.

Please visit answersincme.com/860/240201372-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey Habert, MD, CCFP, FCFP and Maria Anton, RPh, BSc, PharmD. In this activity, experts in type 2 diabetes discuss guideline-recommended goals of treatment and strategies to develop personalized plans that incorporate the latest GLP-1–based therapies. Upon completion of this activity, participants should be better able to: Propose guideline-recommended goals of treatment for adults with T2D; Formulate personalized, evidence-based treatment plans for T2D; and Apply practical strategies for the initiation and integration of contemporary therapies for adults with T2D.

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.

Please visit answersincme.com/YVT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Mak, MD, FRCPC, DRCPSC, FCPA, FAPA, FAASM; and Sabrina Kwon, BSc, MD. In this activity, experts in sleep and primary care discuss strategies for the screening, diagnosis, and treatment of adults with obesity and obstructive sleep apnea. Upon completion of this activity, participants should be better able to: Recognize key clinical and diagnostic challenges in identifying obstructive sleep apnea (OSA) in adults with obesity; Evaluate the role of weight management strategies, including incretin-based therapies, in the comprehensive management of OSA in adults with obesity; and Apply practical, patient-centered approaches to optimize obesity and OSA management across the care pathway.

Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating ICI-based regimens for previously untreated advanced cHL; Interpret the emerging clinical evidence for ICI-based regimens in patients with previously untreated advanced cHL; and Propose how emerging ICI-based regimens, as they become available, may fit into the treatment paradigm for adult and pediatric patients with previously untreated advanced cHL.

Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.

Please visit answersincme.com/NYR860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Liss, MD, MSCP; Denise Black, MD, FRCSC; and Danielle Covarrubias. In this activity, experts in women’s health, joined by a patient advocate, discuss the burden of menopause-related vasomotor symptoms (VMS) and novel management strategies. Upon completion of this activity, participants should be better able to: Identify the impact and burden of VMS as a consequence of menopause; Outline the clinical rationale for novel therapeutic approaches to manage menopause-related VMS; Evaluate the efficacy and safety of novel neurokinin-targeted therapies for treating menopause-related VMS; and Implement patient-centered clinical approaches to improve outcomes for patients experiencing menopause-related VMS.

Please visit answersincme.com/KAF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Trinacty, MD, FRCPC, ABOM. In this activity, an expert in endocrinology discusses incretin-based therapies for the management of cardiometabolic risk. Upon completion of this activity, participants should be better able to: Describe the role of incretin-based therapies in cardiovascular risk reduction; Compare cardiovascular outcomes evidence across incretin-based therapies to inform clinical discussions; and Recognize opportunities to identify and address cardiometabolic risk in a multidisciplinary team setting.

Please visit answersincme.com/860/102701687-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Mike Sharma, MD, MSc; and Richard A. Bernstein, MD, PhD. In this activity, experts in stroke discuss post-stroke care and long-term secondary stroke prevention. Upon completion of this activity, participants should be better able to: Discuss evidence-based strategies for secondary stroke prevention, including risk factor modification; Outline the potential role of FXIa inhibitors in closing current long-term management gaps for patients who have had a non-cardioembolic ischemic stroke or TIA; and Design multidisciplinary, long-term secondary stroke treatment plans that effectively leverage all members of the stroke care team, including cardiologists.